Mixed Data From Chelsea’s Northera Gets It No Closer To Approval
This article was originally published in The Pink Sheet Daily
Executive Summary
Chelsea Therapeutics’ latest data release on its late-stage dizziness treatment for Parkinson’s patients left investors disappointed and raises new questions about the next steps for the drug.